Welcome to the social media community of Menarini Stemline UK Ltd (hereinafter the “Company”).

We value your engagement and encourage an open, respectful dialogue. However, because we operate in a highly regulated industry, we must ensure that all interactions remain safe and compliant with applicable laws and regulations.

By participating in our social media channels and online communities (the “Channels”), you acknowledge and agree to the following terms, which apply in addition to the terms provided by the social platforms themselves. Please note that our Channels are not monitored in real-time; users are solely and exclusively responsible for the data, texts, graphics, pictures, or any other material they decide to post on our Channels (the “Content”).

·         The Company reserves the right to hide, remove, or disable any Content, or block users, at its sole discretion, especially to ensure regulatory compliance or when regular monitoring cannot be guaranteed. In case of repeated or severe violations, we may report users to platform administrators or competent authorities, including disclosing their identity where required by law. The Company is not liable for any loss or damage resulting from Content posted by users.

·         Content published on the Channels is for informational use only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a qualifiedhealth provider regarding a medical condition.

·         Please do not use the Channels to report adverse events or side effects of any drugs. In case of adverse reactions, consult your doctor or pharmacist immediately. You can also report side effects directly to the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help build the knowledge regarding the safety of the medicine. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Menarini Stemline via e-mail (adverseevents@menarinistemline.com) or telephone toll-free on +44(0) 800-047-8675.

·         The Company may contact users for further information if a side effect is mentioned in a post.

·         For specific inquiries regarding the use of our medications, please contact our Medical Information service at medicalinformation@menarinistemline.com rather than posting on the Channels.

·         Content must never mention any specific drug, product, or active ingredient belonging to the Menarini Group or any other pharmaceutical company. Promotional content relating to drugs is strictly prohibited by law.

·         Do not post personal or sensitive information (such as phone numbers or medical histories) about yourself or others. Users are solely responsible for obtaining prior consent from third parties before sharing their information or images. To protect privacy, any Content containing such data will be removed.

·         By posting on our Channels, users grant the Company a free, perpetual, and unrestricted license to use, reproduce, and share their Content on any media for any purposes, including business purposes, without compensation or confidentiality. Users should not submit materials they wish to keep confidential.

·         Content posted by users must not include materials protected by third-party intellectual property rights (e.g., trademarks, music, videos, images) without the express consent of the rightsholders.

·         We will not tolerate any personal attacks, harassment, profanity, or offensive comments directed at the Company’s employees, moderators, or organization. Content that is off-topic, repetitive (spam), or promotes illegal activities will be removed.

·         The Company may provide links to third-party websites; however, we accept no responsibility for the accuracy or content of such sites. The fact that the Company follows, shares, or likes third-party content does not constitute an endorsement or approval of such account or content.

Social media content is subject to rapid obsolescence due to the continuous evolution of scientific innovation. Users are encouraged to refer to the most recent posts and official institutional websites for updated information